Related Articles
IcoSema and the evolution of fixed-ratio insulin–GLP-1 receptor agonist therapies
Once-daily fixed-ratio combination therapies of basal insulin and a GLP-1 receptor agonist such as insulin degludec with liraglutide (IDegLira) and insulin glargine U100 with lixisenatide…
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
In adults with inadequately controlled type 2 diabetes on daily basal insulin therapy, once‑weekly IcoSema showed superiority to once-weekly icodec alone in changes in HbA1c…
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
Once-weekly IcoSema achieved non-inferior HbA1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycaemia rates versus daily BBT, suggesting that there…
The changing spectrum of cardiovascular diseases
Advances in cardiovascular disease prevention are often hailed as one of the major public health accomplishments of the past 50 years. The progress achieved is…
Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial
Weekly LYN-005 provided sustained release of risperidone at therapeutic concentrations with similar bioavailability to immediate-release risperidone. Patients remained clinically stable and no unexpected safety signals…
AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer-From Biology to Breakthrough Therapies
Meeting overview for AACR Special Conference in Cancer Research Discovery and Innovation in Pediatric Cancer- From Biology to Breakthrough Therapies
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Key PointsDespite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T cells have poor outcomes.Future tria
Concurrent limited cutaneous systemic sclerosis and hereditary haemorrhagic telangiectasia
A woman in her fifties attended our institution for evaluation of epistaxis. She had a history of limited cutaneous systemic sclerosis that was diagnosed in…
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomide plus high-dose dexamethasone in patients with newly diagnosed…
